(NASDAQ:AIMT)'s Buy count is 1 and Strong Buy is 6 while the number of analysts recommending Sell and Strong Sell are 0 and 0, respectively. Cantor Fitzgerald started coverage on shares of Aimmune Therapeutics in a research note on Tuesday, December 12th. They generally move extremely slowly and they only produce big price swings when the company produces good or bad trading results, which may only happen a couple of times a year at best. BidaskClub lowered shares of Aimmune Therapeutics from a buy rating to a hold rating in a report on Thursday, January 4th. Analysts mean recommendation for the stock is 1.70. Wedbush reissued an outperform rating and set a $70.00 price objective (up from $42.00) on shares of Aimmune Therapeutics in a report on Monday, October 23rd. Finally, Piper Jaffray Companies upped their price target on shares of Aimmune Therapeutics from $38.00 to $60.00 and gave the stock an overweight rating in a research report on Tuesday, December 5th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company's stock. The stock now has an average rating of Buy and an average price target of $54.22.
Aimmune Therapeutics (AIMT) opened at $31.98 on Tuesday. Following the transaction, the insider now owns 3,750 shares of the company's stock, valued at approximately $138,750. The perception is that the lower the P/E, the higher will be the value of the stock. The stock has a market capitalization of $1,630.00 and a P/E ratio of -12.30.
In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 3,750 shares of Aimmune Therapeutics stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $37.00, for a total value of $138,750.00. Insider ownership decreased by a total of 215866 shares, which suggests that AIMT's key executives are feeling less optimistic about the outlook for the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The disclosure for this sale can be found here.
Analysts are expecting average earnings estimates of $-0.76 for the current quarter based on the opinion of 7 analysts, relating to high earnings per share estimates of $-0.59 and low estimates of $-0.89, however Aimmune Therap Cmn (NASDAQ:AIMT) reported $-0.52 earnings per share for the same quarter previous year. Patters in insider activity can help analysts formulate an outlook for a stock. This is something that Investors should look for in all the stocks they are trading and is an important indicator to keep tabs on. New York State Common Retirement Fund raised its stake in shares of Aimmune Therapeutics by 39.8% in the 2nd quarter. Alliancebernstein L.P. raised its holdings in Aimmune Therapeutics by 109.5% during the 4th quarter.
U.S. stocks were in positive territory most of the session, but began falling about 40 minutes after the Fed released the minutes of last month's policy meeting. Teachers Advisors LLC now owns 63,037 shares of the biotechnology company's stock valued at $1,296,000 after buying an additional 18,688 shares during the period. Daiwa SB Investments Ltd. raised its stake in shares of Aimmune Therapeutics by 44.5% in the fourth quarter. Finally, Vanguard Group Inc. grew its stake in Aimmune Therapeutics by 12.6% during the 2nd quarter.
A number of hedge funds and other institutional investors have recently modified their holdings of AIMT.
COPYRIGHT VIOLATION NOTICE: "Roth Capital Boosts Aimmune Therapeutics (NASDAQ:AIMT) Price Target to $75.00" was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online.
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system created to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.